These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 18836525)

  • 1. Effects of natalizumab treatment on Foxp3+ T regulatory cells.
    Stenner MP; Waschbisch A; Buck D; Doerck S; Einsele H; Toyka KV; Wiendl H
    PLoS One; 2008 Oct; 3(10):e3319. PubMed ID: 18836525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells.
    Putzki N; Baranwal MK; Tettenborn B; Limmroth V; Kreuzfelder E
    Eur Neurol; 2010; 63(5):311-7. PubMed ID: 20453514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level.
    Venken K; Hellings N; Thewissen M; Somers V; Hensen K; Rummens JL; Medaer R; Hupperts R; Stinissen P
    Immunology; 2008 Jan; 123(1):79-89. PubMed ID: 17897326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
    Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
    J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficient CD4+CD25+ T regulatory cell function in patients with abdominal aortic aneurysms.
    Yin M; Zhang J; Wang Y; Wang S; Böckler D; Duan Z; Xin S
    Arterioscler Thromb Vasc Biol; 2010 Sep; 30(9):1825-31. PubMed ID: 20448211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes of regulatory T cells and FoxP3 gene expression in the aging process and its relationship with lung tumors in humans and mice.
    Pan XD; Mao YQ; Zhu LJ; Li J; Xie Y; Wang L; Zhang GB
    Chin Med J (Engl); 2012 Jun; 125(11):2004-11. PubMed ID: 22884069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe immune dysregulation affects CD4⁺CD25(hi)FoxP3⁺ regulatory T cells in HIV-infected patients with low-level CD4 T-cell repopulation despite suppressive highly active antiretroviral therapy.
    Méndez-Lagares G; Pozo-Balado MM; Genebat M; García Pergañeda A; Leal M; Pacheco YM
    J Infect Dis; 2012 May; 205(10):1501-9. PubMed ID: 22457273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes.
    Brusko T; Wasserfall C; McGrail K; Schatz R; Viener HL; Schatz D; Haller M; Rockell J; Gottlieb P; Clare-Salzler M; Atkinson M
    Diabetes; 2007 Mar; 56(3):604-12. PubMed ID: 17327427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
    Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
    J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4+CD25+ regulatory T lymphocytes in malignant pleural effusion.
    Chen YQ; Shi HZ; Qin XJ; Mo WN; Liang XD; Huang ZX; Yang HB; Wu C
    Am J Respir Crit Care Med; 2005 Dec; 172(11):1434-9. PubMed ID: 16151041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation strategies of regulatory T cells for clinical trials: phenotype, function, stability, and expansion capacity.
    Ukena SN; Höpting M; Velaga S; Ivanyi P; Grosse J; Baron U; Ganser A; Franzke A
    Exp Hematol; 2011 Dec; 39(12):1152-60. PubMed ID: 21864487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexamethasone upregulates FOXP3 expression without increasing regulatory activity.
    Prado C; Gómez J; López P; de Paz B; Gutiérrez C; Suárez A
    Immunobiology; 2011 Mar; 216(3):386-92. PubMed ID: 20667622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis.
    Dinh TN; Kyaw TS; Kanellakis P; To K; Tipping P; Toh BH; Bobik A; Agrotis A
    Circulation; 2012 Sep; 126(10):1256-66. PubMed ID: 22851544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
    Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4+Foxp3+ regulatory T cells converted by rapamycin from peripheral CD4+CD25(-) naive T cells display more potent regulatory ability in vitro.
    Chen JF; Gao J; Zhang D; Wang ZH; Zhu JY
    Chin Med J (Engl); 2010 Apr; 123(7):942-8. PubMed ID: 20497692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
    Wipfler P; Oppermann K; Pilz G; Afazel S; Haschke-Becher E; Harrer A; Huemer M; Kunz A; Golaszewski S; Staffen W; Ladurner G; Kraus J
    Mult Scler; 2011 Jan; 17(1):16-23. PubMed ID: 20937631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo expanded regulatory T cells CD4
    Lifshitz GV; Zhdanov DD; Lokhonina AV; Eliseeva DD; Lyssuck EY; Zavalishin IA; Bykovskaia SN
    Autoimmunity; 2016 Sep; 49(6):388-396. PubMed ID: 27424664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro.
    Wang DW; Zhou RB; Yao YM; Zhu XM; Yin YM; Zhao GJ; Dong N; Sheng ZY
    J Pharmacol Exp Ther; 2010 Dec; 335(3):553-61. PubMed ID: 20843956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents.
    de Vries IJ; Castelli C; Huygens C; Jacobs JF; Stockis J; Schuler-Thurner B; Adema GJ; Punt CJ; Rivoltini L; Schuler G; Coulie PG; Lucas S
    Clin Cancer Res; 2011 Feb; 17(4):841-8. PubMed ID: 21177412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization of interleukin-10 or transforming growth factor-β decreases the percentages of CD4+ CD25+ Foxp3+ regulatory T cells in septic mice, thereby leading to an improved survival.
    Hiraki S; Ono S; Tsujimoto H; Kinoshita M; Takahata R; Miyazaki H; Saitoh D; Hase K
    Surgery; 2012 Feb; 151(2):313-22. PubMed ID: 21982068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.